Literature DB >> 19800847

Prevention and management of stroke in very elderly patients.

Nerses Sanossian1, Bruce Ovbiagele.   

Abstract

As the average human lifespan extends and medical care improves, there are more individuals above the age of 80 years who have a high quality of life. However, these very elderly individuals are particularly susceptible to stroke. Identifying ways to optimise the treatment and prevention of acute stroke in these much older people will increasingly be a priority for health-care providers, research funding agencies, and policy makers in years to come. Despite substantial advances in stroke research, with several therapeutic drugs being able to enhance clinical outcomes in people with stroke or who are at risk of stroke, the very elderly seem to receive fewer vascular protection interventions that have been shown to be effective in younger individuals. Although there has been an under-representation of the very elderly in studies of stroke therapy, these treatments might be of benefit to this group of patients. Indeed, emerging data indicate that the use of several of these therapies in routine clinical practice in the very elderly can be effective.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800847     DOI: 10.1016/S1474-4422(09)70259-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  21 in total

1.  Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients ≥ 80 years of age.

Authors:  Gregoire Boulouis; Frederic Dumont; Charlotte Cordonnier; Marie Bodenant; Didier Leys; Hilde Hénon
Journal:  J Neurol       Date:  2011-12-20       Impact factor: 4.849

2.  Navigating the gray zones of stroke management for a graying population.

Authors:  Meng Lee; Bruce Ovbiagele
Journal:  Cerebrovasc Dis       Date:  2010-03-30       Impact factor: 2.762

3.  Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experience.

Authors:  Carole L White; Jeff M Szychowski; Pablo E Pergola; Thalia S Field; Robert Talbert; Helena Lau; Kalyani Peri; Oscar R Benavente
Journal:  J Am Geriatr Soc       Date:  2015-04-06       Impact factor: 5.562

4.  Different impairment of immune and inflammation functions in short and long-term after ischemic stroke.

Authors:  Wen-Xing Li; Fei Qi; Jia-Qian Liu; Gong-Hua Li; Shao-Xing Dai; Tao Zhang; Fei Cheng; Dahai Liu; Song Guo Zheng
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

Review 5.  Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond: Medical and Ethical Issues.

Authors:  Tiberiu A Pana; Jesus A Perdomo-Lampignano; Phyo K Myint
Journal:  Curr Treat Options Neurol       Date:  2019-05-08       Impact factor: 3.598

6.  Management of depression in elderly stroke patients.

Authors:  Johan Lökk; Ahmad Delbari
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 7.  Safety and efficacy of thrombolysis with intravenous alteplase in older stroke patients.

Authors:  Hakan Sarikaya
Journal:  Drugs Aging       Date:  2013-04       Impact factor: 3.923

8.  Use of medications for secondary prevention in stroke patients at hospital discharge in Australia.

Authors:  Ashraf Eissa; Ines Krass; Beata V Bajorek
Journal:  Int J Clin Pharm       Date:  2014-02-12

9.  Social stratification in the dissemination of statins after stroke in Sweden.

Authors:  Maria Sjölander; Marie Eriksson; Eva-Lotta Glader
Journal:  Eur J Clin Pharmacol       Date:  2012-11-28       Impact factor: 2.953

10.  Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.

Authors:  Peter Sandercock; Richard Lindley; Joanna Wardlaw; Martin Dennis; Karen Innes; Geoff Cohen; Will Whiteley; David Perry; Vera Soosay; David Buchanan; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Eivind Berge; Karsten Bruins Slot; Veronica Murray; Andre Peeters; Graeme J Hankey; Karl Matz; Michael Brainin; Stefano Ricci; Teresa A Cantisani; Gordon Gubitz; Stephen J Phillips; Arauz Antonio; Manuel Correia; Phillippe Lyrer; Ingrid Kane; Erik Lundstrom
Journal:  Trials       Date:  2011-11-30       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.